

[Pentamidine](#)

Essential medicine status

Section:

[6. Anti-infective medicines](#) [6.5. Antiprotozoal medicines](#) [6.5.5. Antitrypanosomal medicines](#) [6.5.5.1. African trypanosomiasis](#) [6.5.5.1.1. Medicines for the treatment of 1st stage African trypanosomiasis](#)

ATC codes: [P01CX01](#)

EMLc

Indication

Gambiense trypanosomiasis ICD11 code: [1F51.0](#)

INN

Pentamidine

Medicine type

Chemical agent

List type

Core

Additional notes

To be used for the treatment of Trypanosoma brucei gambiense infection.

Formulations

Parenteral > General injections > IM: 300 mg in vial (as isetionate) powder for injection

EML status history

First added in 1977 ([TRS 615](#))

Changed in 1979 ([TRS 641](#))

Changed in 1987 ([TRS 770](#))

Changed in 1997 ([TRS 882](#))

Changed in 2003 ([TRS 920](#))

Changed in 2007 ([TRS 946](#))

Changed in 2007 ([TRS 950](#))

Changed in 2023 ([TRS 1049](#))

Sex

All

Age

Also recommended for children

Therapeutic alternatives

The recommendation is for this specific medicine

Patent information

Patents have expired in most jurisdictions

Read more [about patents](#).

Wikipedia

[Pentamidine](#)

DrugBank

[Pentamidine](#)

Summary of evidence and Expert Committee recommendations



Following the review of the age-appropriateness of formulations on the EMLc, the Expert Committee recommended the deletion of pentamidine 200 mg powder for injection and the addition of pentamidine 300 mg powder for injection to the EML and EMLc.